Fate Therapeutics - FATE Stock Forecast, Price & News

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on FATE. Robert W. Baird started coverage on shares of Fate Therapeutics in a report on Thursday, June 2nd. They set a "neutral" rating and a $28.00 price objective for the company. Truist Financial dropped their price objective on Fate Therapeutics from $125.00 to $75.00 in a research note on Wednesday, April 13th. Oppenheimer decreased their target price on Fate Therapeutics from $135.00 to $90.00 in a research note on Thursday. Needham & Company LLC began coverage on Fate Therapeutics in a report on Thursday, July 28th. They issued a "hold" rating on the stock. Finally, BMO Capital Markets raised Fate Therapeutics from a "market perform" rating to an "outperform" rating and reduced their price objective for the company from $50.00 to $47.00 in a research report on Monday, July 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Fate Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $75.42.

Fate Therapeutics Trading Up 2.2 %

Shares of FATE Stock traded up $0.72 on Monday, reaching $34.14. 2,008,884 shares of the stock were exchanged, compared to its average volume of 1,457,461. Fate Therapeutics has a one year low of $17.10 and a one year high of $97.43. The stock has a 50 day moving average price of $26.91 and a 200 day moving average price of $31.36.

Insider Buying and Selling

In other Fate Therapeutics news, insider Mark Plavsic sold 3,719 shares of Fate Therapeutics stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $24.61, for a total transaction of $91,524.59. Following the completion of the sale, the insider now owns 127,123 shares of the company's stock, valued at approximately $3,128,497.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Fate Therapeutics news, CEO J Scott Wolchko sold 30,000 shares of Fate Therapeutics stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $32.88, for a total transaction of $986,400.00. Following the transaction, the chief executive officer now directly owns 431,546 shares in the company, valued at $14,189,232.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Plavsic sold 3,719 shares of the stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $24.61, for a total value of $91,524.59. Following the completion of the sale, the insider now owns 127,123 shares of the company's stock, valued at $3,128,497.03. The disclosure for this sale can be found here. Insiders sold a total of 53,082 shares of company stock valued at $1,646,106 over the last ninety days. Insiders own 18.58% of the company's stock.